By the Agency for Healthcare Research and Quality. Join discussion...

Iatrogenic hypoglycemia causes recurrent morbidity in most people with type 1 diabetes and many with type 2 diabetes, and it is sometimes fatal. The barrier of hypoglycemia generally precludes maintenance of euglycemia over a lifetime of diabetes and thus precludes full realization of euglycemia’s long-term benefits. While the clinical presentation is often characteristic, particularly for the experienced individual with diabetes, the neurogenic and neuroglycopenic symptoms of hypoglycemia are Join discussion...

People who manage to reduce their waistlines may also lower their risk for diabetes and heart disease, a study suggests. French researchers found that men and women whose waistlines expanded by 3 inches or more over nine years were at increased risk of developing metabolic syndrome -- a collection of risk factors, including high blood pressure and unhealthy cholesterol levels, that raise a person's odds of diabetes and heart disease. In contrast, women who shed just an inch or more from their Join discussion...

Young diabetic women may be putting their health at risk by skipping insulin jabs in order to lose weight, charity Diabetes UK has warned. One in three female Type 1 diabetes sufferers aged under 30 withhold their own medication, according to a study conducted in Oxford in 1999. Type 1 diabetes sufferers need to inject themselves with insulin several times daily to keep their blood sugars at the requisite level. The practice, dubbed diabulimia, can tip diabetes sufferers into a diabetic coma Join discussion...

Diabetic patients with ST-segment elevation myocardial infarction treated with reperfusion therapy have increased mortality compared with patients without diabetes. The beneficial effects of primary PCI compared with fibrinolysis in diabetic patients are consistent with effects in nondiabetic patients. Join discussion...

Context: Type 1 diabetes is a heterogeneous disorder characterized by severe beta-cell loss. The great majority of patients have type 1A or immune-mediated diabetes. Synthesis: There has been recent progress in defining the genetics, pathogenesis, and natural history of the disease. In addition, there is a major effort to develop immunotherapies to prevent the disorder and to cure the disease with islet transplantation, and there is potential for dramatic improvement in care with introduction of Join discussion...

Diabetes and tuberculosis: an unhealthy partnership Join discussion...

Tracking blood glucose levels, making sense of the numbers and sharing the all-important data with doctors could all get easier for the millions of people living with type 1 and type 2 diabetes, with the launch this month of a new website created by a 24-year-old computer engineer who knows the challenges of the disease firsthand. And that, in turn, could translate into better glycemic control and better outcomes for the rapidly growing number of people-nearly 21 million in the U.S. alone, 194 Join discussion...

On May 21, 2007, the Journal published a meta-analysis by Nissen and Wolski1 that indicated an increased cardiovascular risk associated with rosiglitazone (Avandia), a thiazolidinedione used to treat type 2 diabetes. We published this analysis because it indicated an increase of about 40% in the risk of myocardial infarction among patients receiving rosiglitazone as compared with those receiving either an alternative oral diabetes therapy (metformin or a sulfonylurea) or placebo. Since rosiglita Join discussion...

High-dose immunosuppression and AHST were performed with acceptable toxicity in a small number of patients with newly diagnosed type 1 DM. With AHST, beta cell function was increased in all but 1 patient and induced prolonged insulin independence in the majority of the patients. Join discussion...